BRIEF—Pharming boosts Ruconest supply capacity

Dutch specialty pharma company Pharming has been granted European approval for a new production facility for lead product Ruconest (conestat alfa).

The new facility's post-approval supplement (PAS) for the distribution of Ruconest in the USA is under review, with a decision expected in the first half of 2020.

Chief executive Sijmen de Vries said: "As we continue to see increasing demand for Ruconest in the treatment of hereditary angioedema, we are pleased to announce the approval of our new facility, which will enable us to significantly increase production capacity for supply to patients in the EU.”

“In addition, as a result of our recent re-acquisition of Ruconest’s European distribution rights from Sobi, this capacity expansion will allow us to reach an even greater number of EU patients."